NASDAQ:RNTX Rein Therapeutics Q1 2026 Earnings Report $0.97 -0.04 (-3.96%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$0.97 +0.00 (+0.10%) As of 07/8/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Rein Therapeutics EPS ResultsActual EPS-$0.19Consensus EPS -$0.49Beat/MissBeat by +$0.30One Year Ago EPSN/ARein Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARein Therapeutics Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Rein Therapeutics Earnings HeadlinesRein Therapeutics, IncJune 29, 2026 | edition.cnn.comRein Therapeutics Expands Phase 2 RENEW Trial into United KingdomJune 11, 2026 | globenewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Rein Therapeutics Inc RNTXJune 7, 2026 | morningstar.comMRein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment OptionMay 18, 2026 | globenewswire.comRein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common StockApril 30, 2026 | globenewswire.comSee More Rein Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rein Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rein Therapeutics and other key companies, straight to your email. Email Address About Rein TherapeuticsRein Therapeutics (NASDAQ:RNTX) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity. The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer. In parallel, Rein is advancing additional IL-12-based programs such as RT-102, an IL-12-secreting natural killer (NK) cell therapy, and RT-103, an IL-12-secreting T-cell therapy, each aimed at leveraging distinct immune effector mechanisms. Headquartered in Menlo Park, California, Rein Therapeutics trades on the Nasdaq under the symbol RNTX. The company’s clinical studies are primarily conducted at major cancer centers and academic institutions across North America, with plans to expand its geographic footprint as development progresses. Rein collaborates with leading academic and research institutions to explore combination regimens and identify predictive biomarkers for patient selection. By refining its tunable IL-12 platform, the company seeks to address the unmet needs of patients whose tumors are refractory to existing immunotherapies, building a diversified pipeline of targeted cancer treatments.View Rein Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Exxon Could Be the Market's Next Big Comeback StockWhy Penguin Solutions May Be the Smartest AI Infrastructure StockMeta Platforms’ Cloud Push: Growth Opportunity Versus AI ConcernsThese 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialDrone Stocks Are Down, But Defense Backlogs Tell a Different StoryGE Vernova’s Power Surge Turns the Grid Into an AI Trade2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
